ライフサイエンスコーパス: HAQ

1 HAQ DI scores were used to assess the discriminant valid

2 HAQ score was strongly correlated with depression, pain,

3 HAQ scores (0-3 scale) indicated substantial disability

4 HAQ signaling represents a potential target for the phar

5 ance P < 0.001, COPM satisfaction P < 0.001, HAQ DI P = 0.02) and most work outcomes (RA WIS [P = 0.0

6 h scores from the KFT (rs = 0.48, P < 0.01), HAQ (rs = 0.79, P < 0.01), and all sections of the AHFT

7 ity were found to have 3 characteristics: 1) HAQ disability scores are high at disease onset rather t

8 e onset rather than gradually increasing; 2) HAQ disability increases very slowly over time (0.03 uni

9 is and a 31-question item bank, including 20 HAQ items, the 10-item HAQ-II was developed.

10 (<0.20) for all of the scales of the SF-36, HAQ DI, and SF-6D at 12 months.

11 effect, unadjusted, was a difference of 0.53 HAQ Disability units (scale 0-3) between 100% DMARD use

12 ted with a 2-fold increased odds of having a HAQ score > or =1.00 at 5 years.

13 Abnormal HAQ-DI scores may support patient claims of functional i

14 In early diffuse SSc, the self-administered HAQ-DI is therefore a valuable assessment of function th

15 y characterized 4-hydroxy-2-alkylquinolines (HAQs) previously identified for their antimicrobial acti

16 tions mediating 4-hydroxy-2-alkylquinolines (HAQs) signalling compounds biosynthesis, including 3,4-d

17 he synthesis of 4-hydroxy-2-alkylquinolines (HAQs), including the Pseudomonas quinolone signal (PQS).

18 We subsequently generated an HAQ knock-in mouse expressing a mouse equivalent of the

19 In multivariable analyses, HAQ and other patient self-report measures were signific

20 ith few exceptions, changes in the SF-36 and HAQ scores were different between patients who differed

21 Changes in the SF-36 and HAQ scores were more strongly related to changes in the

22 related significantly with the MOS SF-36 and HAQ, indicating good convergent validity.

23 ted with quartiles from the RADAR, AIMS, and HAQ, providing evidence for the validity of the generic

24 te and the disease-specific RADAR, AIMS, and HAQ.

25 The mean difference between the HAQ and HAQ-II scores was 0.02 units.

26 r smoked had significantly higher Larsen and HAQ scores than did those who lacked the gene and had ne

27 The median scores for the PCS, MCS, and HAQ DI were 36.9, 45.5, and 0.9, respectively.

28 idirectional variation in change in MRSS and HAQ DI score was seen across the spectrum of disease dur

29 ly important changes in the SF-36 scales and HAQ disability scores were determined, which will be use

30 omparison of changes in the SF-36 scales and HAQ scores was made between groups of patients known to

31 est explained by a model with skin score and HAQ-DI (R2 = 0.455).

32 and the tender joint count, DAS28 score, and HAQ score.

33 al remission was achieved (n = 295), average HAQ scores despite clinical remission increased progress

34 A baseline HAQ DI score of > or =1.0 predicted mortality over 4 yea

35 A baseline HAQ DI score of > or =1.0 was predictive of mortality (o

36 ived areas (P = 0.019, adjusted for baseline HAQ score, age, sex, and symptom duration).

37 r of treatment, after adjusting for baseline HAQ score, the patients with early RA who had never take

38 anding RA, even after adjusting for baseline HAQ scores.

39 to examine the relationship of the baseline HAQ DI score to morbidity, mortality, and visceral invol

40 t of the degree of functional disability (by HAQ and SF-36 physical summation scores).

41 on walking knee pain, overall joint pain (by HAQ), and general health status (by QWB) were not signif

42 econd model compared the odds of disability (HAQ score > or =1.00) in treated and untreated patients,

43 ed quality of life (demonstrated by FACIT-F, HAQ DI, and SF-36 scores, respectively) and showed a tre

44 Results yielded a single-factor HAQ-DI score, which favored the current scoring system o

45 oved, with a decrease of 51-60% in TPs, FIQ, HAQ, and VAS scales, and in the number of prescribed dru

46 of recruitment to NOAR: beta coefficient for HAQ 0.13, 95% CI 0.03-0.23, and for DAS28 0.31, 0.12-0.4

47 disease progression than the WOMAC (SES for HAQ = 0.27; SES for WOMAC = -0.05).

48 teria, and 3) substituting grip strength for HAQ scores.

49 ty, and depression in the "patient-friendly" HAQ format.

50 Conversion from HAQ to HAQ-II and from HAQ-II to HAQ for research purposes is simple and reliab

51 Conversion from HAQ to HAQ-II and from HAQ-II to HAQ for research purpos

52 was associated with poorer general function (HAQ; P < 0.0001), more severe pain (P = 0.002), greater

53 Fifty-three percent of patients had HAQ-DI scores > or = 1.0 (signifying moderate-to-severe

54 In the multivariate analysis, higher HAQ scores were associated with depression, and Asians h

55 lower QWB-SA scores and significantly higher HAQ scores than family medicine patients with and withou

56 tly and independently associated with higher HAQ scores, lower Short Form 36 health survey physical f

57 decreasing lean mass associated with higher HAQ scores.

58 Using B cells from homozygous HAQ carriers, we found, surprisingly, that HAQ/HAQ carri

59 uropeans whereas Africans have no homozygous HAQ individuals.

60 000 Genomes Project we found that homozygous HAQ individuals account for approximately 16.1% of East

61 However, HAQ-DI scoring has not been validated.

62 nset, moderate-severe functional impairment (HAQ-DI scores > or = 1.0) was frequent (53%) in this gro

63 corresponding mean changes from baseline in HAQ-DI score were -0.39 and -0.35, as compared with -0.1

64 The reductions from baseline in HAQ-DI scores were greater in the 5-mg and 10-mg tofacit

65 unt (P = 0.005) best explained the change in HAQ DI score over 2 years (R2 = 0.528).

66 disease (r = 0.52, P = 0.003), and change in HAQ disability scores (r = 0.42, P = 0.017).

67 The mean 3-year change in HAQ score was compared by IMD and social class, and inte

68 For the mean (95% CI) 3-year change in HAQ score, a significant interaction exists between IMD

69 The mean difference in HAQ change was most notable between the most deprived (I

70 There was also a significant difference in HAQ score change between patients of the highest (SCI an

71 There was only a modest fall in HAQ scores during pregnancy, with >25% of women having s

72 lted in significantly greater improvement in HAQ scores (P < or = 0.006) and SF-36 physical component

73 oorly, explaining only 5% of the variance in HAQ disability scores.

74 pqsE expression and not only a deficiency in HAQs/PQS production.

75 Increased HAQ-DI scores at baseline were correlated with reduced f

76 ssment Questionnaire (HAQ) disability index (HAQ DI) and the physical component score of the Medical

77 h Assessment Questionnaire disability index (HAQ DI), patient's global assessment of disease activity

78 h Assessment Questionnaire disability index (HAQ-DI) (P = 0.0244) explained the change in skin score

79 h Assessment Questionnaire-Disability Index (HAQ-DI) (which ranges from 0 to 3, with higher scores in

80 h Assessment Questionnaire Disability Index (HAQ-DI) has been well received by the research and clini

81 h Assessment Questionnaire-Disability Index (HAQ-DI) score (scores range from 0 to 3, with higher sco

82 h Assessment Questionnaire Disability Index (HAQ-DI) score, and safety assessments.

83 h Assessment Questionnaire-Disability Index (HAQ-DI) score, the 28-joint Disease Activity Score based

84 h Assessment Questionnaire-Disability Index (HAQ-DI) scores (which range from 0 to 3, with higher sco

85 h Assessment Questionnaire-Disability Index (HAQ-DI; scores range from 0 to 3, with higher scores ind

86 h Assessment Questionnaire disability index [HAQ DI]), and, for those who were employed, the rheumato

87 em bank, including 20 HAQ items, the 10-item HAQ-II was developed.

88 etween anti-CarP antibodies and longitudinal HAQ and DAS28 scores.

89 o achieved either MDA or remission had lower HAQ DI and radiographic scores compared with patients wh

90 ts who were taking OCs at baseline had lower HAQ scores over time than women who were not taking OCs

91 had used OCs before symptom onset had lower HAQ scores throughout followup than patients who had not

92 hose with higher metabolite levels had lower HAQ scores.

93 se during followup was associated with lower HAQ scores over time than no OC use during followup (mea

94 ociations between BMI and CRP (P < 0.001), M-HAQ scores (P = 0.005), and IL-6 concentrations (P = 0.0

95 modified Health Assessment Questionnaire (M-HAQ) and the physical function scale of the Medical Outc

96 modified Health Assessment Questionnaire (M-HAQ) and the Short Form 36 (SF-36) physical function sca

97 modified Health Assessment Questionnaire (M-HAQ) score was 0.6 +/- 0.4 in obese patients compared wi

98 Modified Health Assessment Questionnaire (M-HAQ) scores, demographic characteristics, and employment

99 lation between the latent variable and the M-HAQ was -0.87; between the latent variable and SF-36 phy

100 A latent variable derived from the M-HAQ, the SF-36 physical function scale, and the Steinbro

101 ed from -1.22 for fatigue to -0.03 for the M-HAQ.

102 3 for depression, and 0.73 +/- 0.5 for the M-HAQ.

103 Mean HAQ score was 0.52 units higher for subjects in the high

104 At year 10, mean HAQ score (SD) was 0.57 (0.56); 53% and 14% of patients

105 TLI-treated patients had lower mean HAQ scores at the time of TLI (2.0 versus 2.4; P = 0.000

106 The estimated population mean HAQ DI was 0.25 (95% confidence interval 0.22-0.28), and

107 Functional disability (the mean HAQ DI score) was significantly lower in patients who we

108 Over 10 years, mean HAQ scores were 0.69, 0.72, 0.64, and 0.58 in strategies

109 The median HAQ score was 1.125 (range 0-3).

110 Scleroderma Clinic have completed a modified HAQ annually.

111 Compared with the HAQ, modified HAQ, and Medical Outcomes Study Short Form 36 physical f

112 abatacept regimens resulted in improved MRI, HAQ, and SF-36 scores, with 10 mg/kg showing the greates

113 were reported by 23% of patients and normal HAQ scores by 16% of patients who completed these questi

114 -7.73) were the most important correlates of HAQ-DI scores > or = 1.0.

115 d to the group model, however, the course of HAQ disability became clearer, and 51% of the variance i

116 effect of disease duration on the course of HAQ disability in individual patients.

117 The course of HAQ disability was assessed in 32,525 observations (1,84

118 In some patients, the course of HAQ disability was either 1) chaotic (scores change with

119 The predominant determinants of HAQ disability in RA are disease activity, pain, and psy

120 atively little change in the distribution of HAQ scores from pregnancy to postpartum.

121 ling was used to examine the relationship of HAQ-DI scores to SSc skin and organ system involvement.

122 The reversibility of HAQ scores decreased with the duration of RA (median 100

123 e, biosynthesis, regulation, and activity of HAQs.

124 the biosynthesis of five distinct classes of HAQs, and establish the sequence of synthesis of these c

125 PhnAB synthase, is the primary precursor of HAQs and that the HAQ congener 4-hydroxy-2-heptylquinoli

126 models of the effect of disease duration on HAQ disability were found to have 3 characteristics: 1)

127 iations of appendicular fat and lean mass on HAQ were additive without significant interaction.

128 ct measure, measures of disability and pain (HAQ), and measures of psychological function (AIMS2).

129 es were physician's global assessment, pain, HAQ, patient's global assessment, and acute-phase reacta

130 nts with digital ulcers had worse RCS, pain, HAQ disability (overall, grip, eating, and dressing), ph

131 20% improvement, compared with 71% of paired HAQ observations.

132 In an individual patient, HAQ scores at trial entry represented both reversible an

133 subanalysis of 1092 ACPA-negative patients (HAQ 0.15, 0.02-0.29; DAS28 0.37, 0.11-0.63).

134 ncluded the Health Assessment Questionnaire (HAQ) (physical function), Short Form 36 health survey (S

135 hat for the Health Assessment Questionnaire (HAQ) (range 0-3), were developed (total, and for young a

136 d using the Health Assessment Questionnaire (HAQ) and clinical response was determined based on the A

137 ssed by the Health Assessment Questionnaire (HAQ) and the Short Form 36-item health profile (SF-36),

138 ores on the Health Assessment Questionnaire (HAQ) and the Short Form-36 (SF-36) health survey, the in

139 ndex of the Health Assessment Questionnaire (HAQ) as the measure of function.

140 ncluded the Health Assessment Questionnaire (HAQ) Disability and Discomfort Scales, 10-cm visual anal

141 d using the Health Assessment Questionnaire (HAQ) disability index (DI) and radiographic progression

142 he Stanford Health Assessment Questionnaire (HAQ) Disability Index (DI) at the second time point.

143 The Health Assessment Questionnaire (HAQ) disability index (DI) has been commonly used in rhe

144 The Health Assessment Questionnaire (HAQ) Disability Index (DI) was also an important risk fa

145 SF-36), the Health Assessment Questionnaire (HAQ) disability index (DI), and Mahler's dyspnea index,

146 (FACIT-F), Health Assessment Questionnaire (HAQ) Disability Index (DI), and Short Form 36 (SF-36) in

147 nction, the Health Assessment Questionnaire (HAQ) disability index (DI), and the MRSS were modeled ov

148 0), and the Health Assessment Questionnaire (HAQ) disability index (DI; range 0-3).

149 nths in the Health Assessment Questionnaire (HAQ) disability index (HAQ DI) and the physical componen

150 nd Stanford Health Assessment Questionnaire (HAQ) Disability Index at 5 visits.

151 vey and the Health Assessment Questionnaire (HAQ) disability index at baseline and 6-week followup as

152 The Health Assessment Questionnaire (HAQ) disability index was the strongest clinical predict

153 res for the Health Assessment Questionnaire (HAQ) disability index, were assessed.

154 .0001), and Health Assessment Questionnaire (HAQ) disability scores (r = 0.34, P = 0.03).

155 The Health Assessment Questionnaire (HAQ) has become the most common tool for measuring funct

156 nces in the Health Assessment Questionnaire (HAQ) score at baseline and 3 years by IMD or social clas

157 r RA, had a Health Assessment Questionnaire (HAQ) score collected, and had the RA-specific Disease Ac

158 n, and mean Health Assessment Questionnaire (HAQ) score.

159 details and Health Assessment Questionnaire (HAQ) scores were recorded annually.

160 int counts, Health Assessment Questionnaire (HAQ) scores, C-reactive protein (CRP) levels, and the Di

161 ts, and the Health Assessment Questionnaire (HAQ) were the main measures of disease activity.

162 mpleted the Health Assessment Questionnaire (HAQ), a self report of functional ability.

163 core on the Health Assessment Questionnaire (HAQ), and levels of an acute-phase reactant.

164 n using the Health Assessment Questionnaire (HAQ), and quality of life measurement using the RA Quali

165 ls: QWB-SA, Health Assessment Questionnaire (HAQ), Arthritis Impact Measurement Scales (AIMS), and Ra

166 aire (FIQ), Health Assessment Questionnaire (HAQ), Short Form Health Survey (SF-36), Visual Analogue

167 mpleted the Health Assessment Questionnaire (HAQ), the Arthritis Impact Measurement Scales 2 (AIMS2)

168 ndex of the Health Assessment Questionnaire (HAQ), the Nail Psoriasis Severity Index (NAPSI), the phy

169 ed with the Health Assessment Questionnaire (HAQ), the Valued Life Activities (VLAs), and the Short P

170 ed with the Health Assessment Questionnaire (HAQ), were explored for the total cohort and by sex, con

171 d using the Health Assessment Questionnaire (HAQ), with adjustment for age at symptom onset.

172 completed a Health Assessment Questionnaire (HAQ).

173 mpleted the health assessment questionnaire (HAQ).

174 ssed by the Health Assessment Questionnaire (HAQ).

175 ue from the Health Assessment Questionnaire (HAQ).

176 (DI) of the Health Assessment Questionnaire (HAQ); Disease Activity Score in 28 joints (DAS28); RA WI

177 ndex of the Health Assessment Questionnaire (HAQ-DI) was administered to 134 patients as they entered

178 ding to the Health Assessment Questionnaire [HAQ] disability index [DI]) and health-related quality o

179 al ability (Health Assessment Questionnaire [HAQ] score) and radiographic progression (Sharp-van der

180 , function (Health Assessment Questionnaire [HAQ] score), and RA quality of life (RAQoL) questionnair

181 disability (Health Assessment Questionnaire [HAQ]), and mood (Hospital Anxiety and Depression Scale [

182 The R71H-G230A-R293Q (HAQ) of TMEM173 is the second most common human TMEM173

183 Median (interquartile range) HAQ score was 0.625 (0.125-1.25) and was significantly h

184 Reliability of the RCS, HAQ pain and disability scales, and AIMS2 mood and tensi

185 The mean (+/-SD) HAQ-DI score at entry was 1.04 +/- 0.67.

186 index modified for the spondylarthropathies (HAQ-S; range 0-3).

187 In addition to the standard HAQ questions about disability, the questionnaire includ

188 fter adjusting for age, sex, smoking status, HAQ score, RF positivity, and swollen joint counts (HR 3

189 We conclude that HAQ is a null TMEM173 allele.

190 s HAQ carriers, we found, surprisingly, that HAQ/HAQ carriers express extremely low MPYS protein and

191 The HAQ DI (range of scores 0-3) was measured in a random sa

192 The HAQ DI correlated directly with skin involvement, sclero

193 The HAQ DI is a self-administered questionnaire that SSc pat

194 The HAQ DI score and total skin score at baseline were highl

195 The HAQ DI was correlated with pain (r = 0.58) and global se

196 The HAQ disability index and total knee score were more sens

197 The HAQ showed high internal consistency and high concurrent

198 The HAQ was repeated after 1, 2, 3, 5, 7, 10, 12, 15, and 20

199 The HAQ-DI scores (month 3) and DAS28-4(ESR) less than 2.6 r

200 The HAQ-II can be used in all places where the HAQ is now us

201 The HAQ-II is a reliable and valid 10-item questionnaire tha

202 The HAQ-II performed as well as the HAQ in a clinical trial

203 The HAQ-II was reliable (reliability of 0.88, compared with

204 Although the HAQ DI score was heavily influenced by hand dysfunction

205 Although the HAQ is a useful clinical tool and a central measure of d

206 By Cox regression analysis, the HAQ DI was one of the best predictors of survival.

207 baseline vitamin D metabolite levels and the HAQ score; that is, those with higher metabolite levels

208 nnaire that performs at least as well as the HAQ and is simpler to administer and score.

209 The HAQ-II performed as well as the HAQ in a clinical trial and in prediction of mortality a

210 an irreversible component by associating the HAQ score during remission with 2 measures associated wi

211 The mean difference between the HAQ and HAQ-II scores was 0.02 units.

212 ls of physical disability as measured by the HAQ (P < 0.001).

213 ased burden of disability as measured by the HAQ and higher disease activity in patients with inflamm

214 proving physical function as measured by the HAQ DI over 24 months of treatment.

215 easured by GCSE grades and negatively by the HAQ DI score (t = 10.94, P = 6.36 x 10(-16) ).

216 ity/severity (particularly as defined by the HAQ DI) was important, smoking was the most consistent i

217 rted physical disability, as measured by the HAQ, occurs as a function of disease acting over time do

218 Consequently, the HAQ/HAQ B cells do not respond to CDNs.

219 n, mortality would be reduced by 50% for the HAQ and by 33% for global disease severity if patients i

220 rtaken to establish normative values for the HAQ DI in a general population and to analyze its correl

221 28 [CRP] of <2.6, 71.8% versus 66.8% for the HAQ DI, and 9.7 versus 10.6 and 7.3 versus 7.2, respecti

222 iability of 0.88, compared with 0.83 for the HAQ), measured disability over a longer scale than the H

223 placebo group were also significant for the HAQ-DI score and the DAS28-CRP but not for an SDAI score

224 Five original items from the HAQ were retained.

225 s study, the disability index (DI) (from the HAQ) and the VAS scores (on a 0-3 scale) were compared w

226 d validate a revised version of the HAQ (the HAQ-II).

227 However, the HAQ is long (34 questions, including 20 concerning activ

228 radiographic scores, but differences in the HAQ and RAQoL scores were maintained (P < 0.05).

229 hieved the MCID compared with placebo in the HAQ DI score (30.9% versus 14.8%), transitional dyspnea

230 n coefficient 0.368), as were changes in the HAQ DI score and the total skin score over 2 years (corr

231 Improvement in the HAQ DI score in these patients with diffuse scleroderma

232 d at 2 years, improvement (reduction) in the HAQ DI score over 2 years was related to factors other t

233 s well as the relationship of changes in the HAQ DI score to changes in physical examination, laborat

234 12 months and 24 months; improvement in the HAQ DI with LEF4(-0.60) was statistically significantly

235 ment for baseline scores, differences in the HAQ DI, SF-36 role physical, general health, vitality, r

236 ovement from baseline of at least 0.3 in the HAQ disability index (47.3 percent vs. 23.3 percent, P<0

237 A 1-SD change in the HAQ resulted in a much larger increase in the odds ratio

238 There were also greater reductions in the HAQ-DI score at month 3 and higher percentages of patien

239 The mean change in the HAQ-DI score was -0.35 in the 5-mg tofacitinib group and

240 y >6 times with each 1-point increase in the HAQ-S.

241 evelop and validate a revised version of the HAQ (the HAQ-II).

242 n mouse expressing a mouse equivalent of the HAQ allele (mHAQ).

243 ded within 3 months of administration of the HAQ and VAS, using t-tests and Spearman's correlation te

244 The normative values of the HAQ DI that we have presented could be used as a referen

245 d to groups of patients) explains 37% of the HAQ disability score variation.

246 Aspects of the HAQ's psychometric properties were evaluated.

247 as to examine the structural validity of the HAQ-DI and evaluate the latent factors underlying HAQ-DI

248 t study provides the first validation of the HAQ-DI scoring system as determined by its latent factor

249 ch favored the current scoring system of the HAQ-DI.

250 n large part the "floor effects" seen on the HAQ and MHAQ, and are useful to screen for problems with

251 ed for other major secondary end points (the HAQ and the SF-36), the NAPSI, the physician's global as

252 ar study from routine clinical practice, the HAQ was the most powerful predictor of mortality, follow

253 y Short Form 36 physical function scale, the HAQ-II was as well correlated or better correlated with

254 We studied the HAQ-II in 14,038 patients with rheumatic disease over a

255 ured disability over a longer scale than the HAQ, and had no nonfitting items and no gaps.

256 s the primary precursor of HAQs and that the HAQ congener 4-hydroxy-2-heptylquinoline (HHQ) is the di

257 We tested the concept that the HAQ has a reversible and an irreversible component by as

258 e ACR 20% response rates are higher when the HAQ, rather than grip strength, is used to measure physi

259 e HAQ-II can be used in all places where the HAQ is now used, and it may prove to be easier to use in

260 5 observations (1,843 patients) in which the HAQ was administered.

261 Prospective studies with the HAQ administered at regular intervals, as in controlled

262 d favorable measurement properties, with the HAQ having the advantages of being more sensitive to cha

263 relationship with 1,25(OH)(2)D was with the HAQ score.

264 Compared with the HAQ, modified HAQ, and Medical Outcomes Study Short Form

265 Conversion from HAQ to HAQ-II and from HAQ-II to HAQ for research purposes is s

266 ersion from HAQ to HAQ-II and from HAQ-II to HAQ for research purposes is simple and reliable.

267 I and evaluate the latent factors underlying HAQ-DI scoring.

268 Mean scores +/- SDs on instruments were: HAQ 0.73 +/- 0.69; MCS 49 +/- 12; and PCS 33 +/- 11.

269 versible and irreversible impairments, while HAQ scores at the time of RA remission represented the m

270 rall, the MRSS improves during trials, while HAQ DI scores and lung function are mostly static.

271 and social class and their association with HAQ scores (P = 0.001) to modify outcome: IMD1/SC I and

272 the strongest association per kilogram with HAQ.

273 nd positive associations were also seen with HAQ scores, but these did not meet statistical significa

274 s from more deprived areas had poorer 3-year HAQ outcome than those from less deprived areas (P = 0.0